The increasing popularity of weight-loss drugs including Ozempic and Wegovy has businesses scrambling to adapt to the new shopping habits of thinner, less-hungry customers.
Although glucagon-like peptide-1 agonists, known as GLP-1 drugs, were developed to treat chronic conditions like diabetes and heart disease, a May survey by the nonprofit health policy organization KFF found 40% of respondents said they mainly used them to slim down.
